Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SuDDICU trial of selective decontamination of the digestive tract in mechanically ventilated ICU patients
ACTRN12615000411549Phase 3Recruiting
- Sponsor
- The George Institute for Global Health
- Start
- May 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of colistin, tobramycin, nystatin, cefotaxime, ceftriaxone and 1 more in critical illness and Infection (2 arms), sponsored by The George Institute for Global Health. Primary endpoint: All-cause mortality at hospital discharge. Started May 2017; status: recruiting.
02
Drugs
colistintobramycinnystatincefotaximeceftriaxone
03
Conditions
critical illnessInfection
Beyond the preview
Go deeper on ACTRN12615000411549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000411549.